Pharmacogenomics
Part of a series on |
Genetics |
---|
Pharmacogenomics, often abbreviated "PGx," is the study of the role of the
Pharmacogenomics aims to develop rational means to optimize
Whether used to explain a patient's response (or lack of it) to a treatment, or to act as a predictive tool, it hopes to achieve better treatment outcomes and greater efficacy, and reduce drug toxicities and adverse drug reactions (ADRs). For patients who do not respond to a treatment, alternative therapies can be prescribed that would best suit their requirements. In order to provide pharmacogenomic recommendations for a given drug, two possible types of input can be used: genotyping, or exome or whole genome sequencing.[10] Sequencing provides many more data points, including detection of mutations that prematurely terminate the synthesized protein (early stop codon).[10]
Pharmacogenetics vs. pharmacogenomics
The term pharmacogenomics is often used interchangeably with pharmacogenetics. Although both terms relate to drug response based on genetic influences, there are differences between the two. Pharmacogenetics is limited to
Mechanisms of pharmacogenetic interactions
Pharmacokinetics
Pharmacokinetics involves the absorption, distribution, metabolism, and elimination of pharmaceutics. These processes are often facilitated by enzymes such as drug transporters or drug metabolizing enzymes (discussed in-depth below). Variation in DNA loci responsible for producing these enzymes can alter their expression or activity so that their functional status changes. An increase, decrease, or loss of function for transporters or metabolizing enzymes can ultimately alter the amount of medication in the body and at the site of action. This may result in deviation from the medication's therapeutic window and result in either toxicity or loss of effectiveness.
Drug-metabolizing enzymes
The majority of clinically actionable pharmacogenetic variation occurs in genes that code for drug-metabolizing enzymes, including those involved in both
Drug transporters
Many medications rely on
Pharmacodynamics
Pharmacodynamics refers to the impact a medication has on the body, or its mechanism of action.
Drug targets
Drug targets are the specific sites where a medication carries out its pharmacological activity. The interaction between the drug and this site results in a modification of the target that may include inhibition or potentiation.[15] Most of the pharmacogenetic interactions that involve drug targets are within the field of oncology and include targeted therapeutics designed to address somatic mutations (see also Cancer Pharmacogenomics). For example, EGFR inhibitors like gefitinib (Iressa) or erlotinib (Tarceva) are only indicated in patients carrying specific mutations to EGFR.[16][17]
Germline mutations in drug targets can also influence response to medications, though this is an emerging subfield within pharmacogenomics. One well-established gene-drug interaction involving a germline mutation to a drug target is warfarin (Coumadin) and VKORC1, which codes for vitamin K epoxide reductase (VKOR). Warfarin binds to and inhibits VKOR, which is an important enzyme in the vitamin K cycle.[18] Inhibition of VKOR prevents reduction of vitamin K, which is a cofactor required in the formation of coagulation factors II, VII, IX and X, and inhibitors protein C and S.[18][19]
Off-target sites
Medications can have off-target effects (typically unfavorable) that arise from an interaction between the medication and/or its metabolites and a site other than the intended target.[20] Genetic variation in the off-target sites can influence this interaction. The main example of this type of pharmacogenomic interaction is glucose-6-phosphate-dehydrogenase (G6PD). G6PD is the enzyme involved in the first step of the pentose phosphate pathway which generates NADPH (from NADP). NADPH is required for the production of reduced glutathione in erythrocytes and it is essential for the function of catalase.[21] Glutathione and catalase protect cells from oxidative stress that would otherwise result in cell lysis. Certain variants in G6PD result in G6PD deficiency, in which cells are more susceptible to oxidative stress. When medications that have a significant oxidative effect are administered to individuals who are G6PD deficient, they are at an increased risk of erythrocyte lysis that presents as hemolytic anemia.[22]
Immunologic
The human leukocyte antigen (HLA) system, also referred to as the major histocompatibility complex (MHC), is a complex of genes important for the adaptive immune system. Mutations in the HLA complex have been associated with an increased risk of developing hypersensitivity reactions in response to certain medications.[23]
Clinical pharmacogenomics resources
Clinical Pharmacogenetics Implementation Consortium (CPIC)
The Clinical Pharmacogenetics Implementation Consortium (CPIC) is "an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care. CPIC’s goal is to address barriers to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines. CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated."[12]
The CPIC guidelines are "designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered. A key assumption underlying the CPIC guidelines is that clinical high-throughput and pre-emptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients’ genotypes available even if they have not explicitly ordered a test with a specific drug in mind. CPIC's guidelines, processes and projects have been endorsed by several professional societies."[12]
U.S. Food and Drug Administration
Table of Pharmacogenetic Associations
In February 2020 the FDA published the Table of Pharmacogenetic Associations.[24] For the gene-drug pairs included in the table, "the FDA has evaluated and believes there is sufficient scientific evidence to suggest that subgroups of patients with certain genetic variants, or genetic variant-inferred phenotypes (such as affected subgroup in the table below), are likely to have altered drug metabolism, and in certain cases, differential therapeutic effects, including differences in risks of adverse events."[25]
"The information in this Table is intended primarily for prescribers, and patients should not adjust their medications without consulting their prescriber. This version of the table is limited to pharmacogenetic associations that are related to drug metabolizing enzyme gene variants, drug transporter gene variants, and gene variants that have been related to a predisposition for certain adverse events. The FDA recognizes that various other pharmacogenetic associations exist that are not listed here, and this table will be updated periodically with additional pharmacogenetic associations supported by sufficient scientific evidence."[25]
Table of Pharmacogenomic Biomarkers in Drug Labeling
The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling lists FDA-approved drugs with pharmacogenomic information found in the drug labeling. "Biomarkers in the table include but are not limited to germline or somatic gene variants (polymorphisms, mutations), functional deficiencies with a genetic etiology, gene expression differences, and chromosomal abnormalities; selected protein biomarkers that are used to select treatments for patients are also included."[26]
PharmGKB
The Pharmacogenomics Knowledgebase (PharmGKB) is an "NIH-funded resource that provides information about how human genetic variation affects response to medications. PharmGKB collects, curates and disseminates knowledge about clinically actionable gene-drug associations and genotype-phenotype relationships."[27]
Commercial Pharmacogenetic Testing Laboratories
There are many commercial laboratories around the world who offer pharmacogenomic testing as a laboratory developed test (LDTs). The tests offered can vary significantly from one lab to another, including genes and alleles tested for, phenotype assignment, and any clinical annotations provided. With the exception of a few direct-to-consumer tests, all pharmacogenetic testing requires an order from an authorized healthcare professional. In order for the results to be used in a clinical setting in the United States, the laboratory performing the test much be CLIA-certified. Other regulations may vary by country and state.
Direct-to-Consumer Pharmacogenetic Testing
Common Pharmacogenomic-Specific Nomenclature
Genotype
There are multiple ways to represent a pharmacogenomic genotype. A commonly used nomenclature system is to report haplotypes using a star (*) allele (e.g., CYP2C19 *1/*2). Single-nucleotide polymorphisms (SNPs) may be described using their assignment reference SNP cluster ID (rsID) or based on the location of the base pair or amino acid impacted.[29]
Phenotype
In 2017 CPIC published results of an expert survey to standardize terms related to clinical pharmacogenetic test results.[30] Consensus for terms to describe allele functional status, phenotype for drug metabolizing enzymes, phenotype for drug transporters, and phenotype for high-risk genotype status was reached.
Applications
The list below provides a few more commonly known applications of pharmacogenomics:[31]
- Improve drug safety, and reduce ADRs;
- Tailor treatments to meet patients' unique genetic pre-disposition, identifying optimal dosing;
- Improve drug discovery targeted to human disease; and
- Improve proof of principle for efficacy trials.
Pharmacogenomics may be applied to several areas of medicine, including pain management, cardiology, oncology, and psychiatry. A place may also exist in forensic pathology, in which pharmacogenomics can be used to determine the cause of death in drug-related deaths where no findings emerge using autopsy.[citation needed]
In
In cardiovascular disorders, the main concern is response to drugs including warfarin, clopidogrel, beta blockers, and statins.[10] In patients with CYP2C19, who take clopidogrel, cardiovascular risk is elevated, leading to medication package insert updates by regulators.[34] In patients with type 2 diabetes, haptoglobin (Hp) genotyping shows an effect on cardiovascular disease, with Hp2-2 at higher risk and supplemental vitamin E reducing risk by affecting HDL.[35]
In psychiatry, as of 2010, research has focused particularly on 5-HTTLPR and DRD2.[36]
Clinical implementation
Initiatives to spur adoption by clinicians include the Ubiquitous Pharmacogenomics (U-PGx) program in Europe and the Clinical Pharmacogenetics Implementation Consortium (CPIC) in the United States.[37] In a 2017 survey of European clinicians, in the prior year two-thirds had not ordered a pharmacogenetic test.[38]
In 2010, Vanderbilt University Medical Center launched Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment (PREDICT);[39] in 2015 survey, two-thirds of the clinicians had ordered a pharmacogenetic test.[40]
In 2019, the largest private health insurer, UnitedHealthcare, announced that it would pay for genetic testing to predict response to psychiatric drugs.[41]
In 2020, Canada's 4th largest health and dental insurer, Green Shield Canada, announced that it would pay for pharmacogenetic testing and its associated clinical decision support software to optimize and personalize mental health prescriptions.[42]
Reduction of polypharmacy
A potential role for pharmacogenomics is to reduce the occurrence of polypharmacy: it is theorized that with tailored drug treatments, patients will not need to take several medications to treat the same condition. Thus they could potentially reduce the occurrence of adverse drug reactions, improve treatment outcomes, and save costs by avoiding purchase of some medications. For example, maybe due to inappropriate prescribing, psychiatric patients tend to receive more medications than age-matched non-psychiatric patients.[43]
The need for pharmacogenomically tailored drug therapies may be most evident in a survey conducted by the Slone Epidemiology Center at Boston University from February 1998 to April 2007. The study elucidated that an average of 82% of adults in the United States are taking at least one medication (prescription or nonprescription drug, vitamin/mineral, herbal/natural supplement), and 29% are taking five or more. The study suggested that those aged 65 years or older continue to be the biggest consumers of medications, with 17-19% in this age group taking at least ten medications in a given week. Polypharmacy has also shown to have increased since 2000 from 23% to 29%.[44]
Example case studies
Case A – Antipsychotic adverse reaction[45]
Patient A has schizophrenia. Their treatment included a combination of ziprasidone, olanzapine, trazodone and
Case B – Pain Management[46]
Patient B is a woman who gave birth by caesarian section. Her physician prescribed codeine for post-caesarian pain. She took the standard prescribed dose, but she experienced nausea and dizziness while she was taking codeine. She also noticed that her breastfed infant was lethargic and feeding poorly. When the patient mentioned these symptoms to her physician, they recommended that she discontinue codeine use. Within a few days, both the patient's and her infant's symptoms were no longer present. It is assumed that if the patient had undergone a pharmacogenomic test, it would have revealed she may have had a duplication of the gene CYP2D6, placing her in the Ultra-rapid metabolizer (UM) category, explaining her reactions to codeine use.
Case C – FDA Warning on Codeine Overdose for Infants[47]
On February 20, 2013, the
Challenges
Although there appears to be a general acceptance of the basic tenet of pharmacogenomics amongst physicians and healthcare professionals,[49] several challenges exist that slow the uptake, implementation, and standardization of pharmacogenomics. Some of the concerns raised by physicians include:[50][49][51]
- Limitation on how to apply the test into clinical practices and treatment;
- A general feeling of lack of availability of the test;
- The understanding and interpretation of evidence-based research;
- Combining test results with other patient data for prescription optimization; and
- Ethical, legal and social issues.
Issues surrounding the availability of the test include:[48]
- The lack of availability of scientific data: Although there are a considerable number of drug-metabolizing enzymes involved in the metabolic pathways of drugs, only a fraction have sufficient scientific data to validate their use within a clinical setting; and
- Demonstrating the cost-effectiveness of pharmacogenomics: Publications for the pharmacoeconomics of pharmacogenomics are scarce, therefore sufficient evidence does not at this time exist to validate the cost-effectiveness and cost-consequences of the test.
Although other factors contribute to the slow progression of pharmacogenomics (such as developing guidelines for clinical use), the above factors appear to be the most prevalent. Increasingly substantial evidence and industry body guidelines for clinical use of pharmacogenetics have made it a population wide approach to precision medicine. Cost, reimbursement, education, and easy use at the point of care remain significant barriers to widescale adoption.
Controversies
Race-based medicine
There has been call to move away from race and ethnicity in medicine and instead use genetic ancestry as a way to categorize patients.
Genetic exceptionalism
In the early 2000s, handling genetic information as exceptional, including legal or regulatory protections, garnered strong support. It was argued that genomic information may need special policy and practice protections within the context of electronic health records (EHRs).[55] In 2008, the Genetic Information Nondiscrimination Act (GINA) was enacted to protect patients from health insurance companies discriminating against an individual based on genetic information.[56][57]
More recently it has been argued that genetic exceptionalism is past its expiration date as we move into a blended genomic/big data era of medicine, yet exceptionalism practices continue to permeate clinical healthcare today.[58][59] Garrison et al. recently relayed a call to action to update verbiage from genetic exceptionalism to genomic contextualism in that we recognize a fundamental duality of genetic information.[60] This allows room in the argument for different types of genetic information to be handled differently while acknowledging that genomic information is similar and yet distinct from other health-related information.[60] Genomic contextualism would allow for a case-by-case analysis of the technology and the context of its use (e.g., clinical practice, research, secondary findings).
Others argue that genetic information is indeed distinct from other health-related information but not to the extent of requiring legal/regulatory protections, similar to other sensitive health-related data such as HIV status.[61] Additionally, Evans et al. argue that the EHR has sufficient privacy standards to hold other sensitive information such as social security numbers and that the fundamental nature of an EHR is to house highly personal information.[58] Similarly, a systematic review reported that the public had concern over privacy of genetic information, with 60% agreeing that maintaining privacy was not possible; however, 96% agreed that a direct-to-consumer testing company had protected their privacy, with 74% saying their information would be similarly or better protected in an EHR. With increasing technological capabilities in EHRs, it is possible to mask or hide genetic data from subsets of providers and there is not consensus on how, when, or from whom genetic information should be masked.[55][62] Rigorous protection and masking of genetic information is argued to impede further scientific progress and clinical translation into routine clinical practices.[63]
History
Pharmacogenomics was first recognized by
The first FDA approval of a pharmacogenetic test was in 2005[9] (for alleles in CYP2D6 and CYP2C19)
Future
Computational advances have enabled cheaper and faster sequencing.[70] Research has focused on combinatorial chemistry,[71] genomic mining, omic technologies, and high throughput screening.
As the cost per genetic test decreases, the development of personalized drug therapies will increase.[72] Technology now allows for genetic analysis of hundreds of target genes involved in medication metabolism and response in less than 24 hours for under $1,000. This a huge step towards bringing pharmacogenetic technology into everyday medical decisions. Likewise, companies like deCODE genetics, MD Labs Pharmacogenetics, Navigenics and 23andMe offer genome scans. The companies use the same genotyping chips that are used in GWAS studies and provide customers with a write-up of individual risk for various traits and diseases and testing for 500,000 known SNPs. Costs range from $995 to $2500 and include updates with new data from studies as they become available. The more expensive packages even included a telephone session with a genetics counselor to discuss the results.[73]
Ethics
Pharmacogenetics has become a controversial issue in the area of bioethics. Privacy and confidentiality are major concerns.[74] The evidence of benefit or risk from a genetic test may only be suggestive, which could cause dilemmas for providers.[74]: 145 Drug development may be affected, with rare genetic variants possibly receiving less research.[74] Access and patient autonomy are also open to discussion.[75]: 680
Web-based resources
Data source | Main use | Citation |
---|---|---|
PharmVar | A central repository for pharmacogene variation that focuses on haplotype structure and allelic variation | [78] |
SuperCYP Bioinformatics Tool | Containing 1170 drugs with more than 3800 interactions, and approximately 2000 known SNPs. These SNPs are listed and ordered according to their effect on expression and/or activity. | [79] |
PharmGKB | The Pharmacogenomics Knowledge Base (PharmGKB) is an interactive tool for researchers investigating how genetic variation affects drug response. | [80] |
dbSNP database | A repository of SNPs and other variants that have been reported after discovery, compiled and officially named. These are SNPs across the board. |
[81][82] |
FINDbase | Repository of allele frequencies of pharmacogenetic markers in different populations | [83] |
Pharmacogenomics Biomarkers in Drug Labelling | A table that identifies which FDA-approved drugs have pharmacogenomics-related warning labels | [84] |
SNPedia | A wiki-based bioinformatics database of SNPs | [85][86] |
Pharmacogenomics Research Network (PGRN) | The PGRN hosts resources and information to stimulate collaborative research in pharmacogenomics and precision medicine. | [87] |
See also
- Genomics
- Metabolomics
- Pharmacovigilance
- Population groups in biomedicine
- Toxgnostics
- Medical terminology
- HL7
- FHIR
References
- ISBN 978-981-4675-80-2.
- ^ S2CID 15195039.
- ^ "Center for Pharmacogenomics and Individualized Therapy". Unc Eshelman School of Pharmacy. Retrieved 2014-06-25.
- ^ "overview of pharmacogenomics". Up-to-Date. May 16, 2014. Retrieved 2014-06-25.
- PMID 19530963.
- PMID 19565025.
- PMID 29249361.
- U.S. Food and Drug Administration. March 2005. Retrieved 2008-08-27.
- ^ PMID 20712531.
- ^ PMID 24303303.
- ^ PMID 23333322.
- ^ a b c "Clinical Pharmacogenetics Implementation Consortium". cpicpgx.org. Retrieved 2022-12-13.
- ^ PMID 25475361.
- PMID 35152405.
- PMC 7120710.
- ^ Iressa [package insert]. Wilmington, DE: Astra Zeneca; 2021.
- ^ Tarceva [package insert]. Northbrook, IL: OSI Pharmaceuticals, LLC; 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
- ^ PMID 18374189.
- PMID 9780555.
- S2CID 11858945.
- PMID 35529053.
- PMID 36049896.
- PMID 22920398.
- ^ Office of the Commissioner (2020-03-24). "FDA Announces Collaborative Review of Scientific Evidence to Support Associations Between Genetic Information and Specific Medications". FDA. Retrieved 2022-12-13.
- ^ a b Center for Devices and Radiological Health (2022-10-26). "Table of Pharmacogenetic Associations". FDA.
- ^ Center for Drug Evaluation and Research (2022-08-11). "Table of Pharmacogenomic Biomarkers in Drug Labeling". FDA.
- ^ "PharmGKB". PharmGKB. Retrieved 2022-12-13.
- ^ Center for Drug Evaluation and Research (2021-06-25). "Direct-to-Consumer Tests". FDA.
- PMID 22369494.
- PMID 27441996.
- ISBN 978-1934115046.
- PMID 20920994.
- S2CID 25362813.
- PMID 28520346. Bookshelf ID: NBK84114.
- PMID 30386783.
- ^ Malhotra AK (2010). "The state of pharmacogenetics". Psychiatr Times. 27 (4): 38–41, 62.
- S2CID 73460688.
- PMID 28669097.
- PMID 22876213.
- PMID 26261062.
- ^ "Pharmacogenetic test makers cheer UnitedHealth coverage. Other payers aren't there yet". MedTech Dive. Retrieved 2019-12-29.
- ^ "Personalized drug treatment through pharmacogenetics".
- ISBN 978-94-007-5804-9.
- ^ "Patterns of Medication Use in the United States". Boston University, Slone Epidemiology Center. 2006.
- PMID 19300635.
- ^ "Pharmacogenetics: increasing the safety and effectiveness of drug therapy [Brochure]" (PDF). American Medical Association. 2011.
- ^ "FDA Drug Safety Communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy". United States Food and Drug Administration. 2013-02-20.
- ^ PMID 17696640.
- ^ S2CID 21366195.
- ^ "Center for Genetics Education".[permanent dead link]
- S2CID 1212666.
- PMID 33406325.
- S2CID 218583019.
- ^ "LCD - Molecular Pathology Procedures (L35000)". www.cms.gov. Retrieved 2022-12-13.
- ^ S2CID 29833634.
- ^ "The Genetic Information Nondiscrimination Act of 2008". US EEOC. Retrieved 2022-12-13.
- S2CID 205121202.
- ^ S2CID 32998031.
- S2CID 59250873.
- ^ PMID 30676903.
- S2CID 34092673.
- PMID 31591640.
- PMID 31956328.
- ^ PMID 11678777.
- PMID 22461095.
- PMID 13697554.
- S2CID 21761285.
- ^ Vogel F (1959). "Moderne probleme der humangenetik" [Modern human genetics problems]. Ergebnisse der Inneren Medizin und Kinderheilkunde [Results of internal medicine and pediatrics] (in German). Berlin, Heidelberg: Springer: 52–125.
- PMID 16421980.
- ISBN 978-1-57444-878-8.
- S2CID 1740692.
- PMID 17168846.
- ISBN 978-0-465-02550-3.
- ^ PMID 15738433.
- S2CID 6149591.
- S2CID 46120003.
- ISBN 978-1-4614-9442-3.
- PMID 29134625.
- PMID 19934256.
- )
- ^ "DBSNP Home Page". National Center for Biotechnology Information, U.S. National Library of Medicine.
- PMID 10592272.
- PMID 24234438.
- ^ "Table of Pharmacogenomic Biomarkers in Drug Labeling". FDA. 18 August 2021.
- ^ "SNPedia".
- PMID 22140107.
- ^ "Pharmacogenomics Research Network PGRN".
Further reading
- Katsnelson A (August 2005). "A Drug to Call One's Own: Will medicine finally get personal?". Scientific American.
- Karczewski KJ, Daneshjou R, Altman RB (2012). "Chapter 7: Pharmacogenomics". PLOS Computational Biology. 8 (12): e1002817. PMID 23300409.
External links
- "Pharmacogenomics Factsheet". National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Retrieved 2011-07-11.
a quick introduction to customised drugs
- "Pharmacogenomics Education Initiatives". U.S. Food and Drug Administration. 2010-09-24. Retrieved 2011-07-11.
- "Personalized Medicine (Pharmacogenetics)". University of Utah's Genetic Science Learning Center. Archived from the original on 2011-05-19. Retrieved 2011-07-11.
- "Center for Pharmacogenomics and Individualized Therapy". University of North Carolina at Chapel Hill Center for Pharmacogenomics and Individualized Therapy. Archived from the original on 2014-08-06. Retrieved 2014-06-25.
Journals:
- "Pharmacogenomics". Future Medicine Ltd. 24 August 2023.
- "Pharmacogenetics and Genomics". Lippincott Williams & Wilkins. ISSN 1744-6872.
- "The Pharmacogenomics Journal". The Pharmacogenomics Journal. Nature Publishing Group. 20 October 2021. ISSN 1470-269X.